Cook Medical launches new treatment option for otolaryngologists

Cook Medical has launched a new treatment option for otolaryngologists (ear, nose and throat specialists) who repair the dura mater following cerebrospinal fluid (CSF) leaks at the base of the skull. Cook's Biodesign® Duraplasty Graft is the latest Biodesign product from Cook Medical's Otolaryngology—Head and Neck Surgery (OHNS) clinical division.

A dura substitute, the Biodesign Duraplasty Graft is used to repair the dura mater and prevent CSF leaks following surgical procedures at the skull base (e.g. tumor resection). In other cases, the graft may be used to treat existing CSF leaks such as those resulting from trauma or sinus surgery at the skull base.

During the repair procedure, the Biodesign graft is easy to manipulate, because of its advanced handling characteristics. The graft doesn't swell when hydrated and doesn't fold onto itself. The graft can be placed with or without sutures and can achieve a strong seal, so it provides a well-balanced treatment option for dura mater repair at the skull base. Another benefit of Biodesign is that it reduces the need to harvest tissue from other parts of the body for use in the repair.

"I started using Biodesign because I found it easier to handle during the endoscopic repair than competing products," said Bradford A. Woodworth, M.D., director of otolaryngology research at the University of Alabama at Birmingham, in a letter to the U.S. Food and Drug Administration in which he evaluated the new device. "Although not directly measured, [I] feel it contributes to faster graft placement and increased operative speed."

"Biodesign's proven tissue repair technology works in different grafting procedures," said Thomas Cherry, R.N., OHNS global clinical division leader for Cook Medical. "We're excited to introduce the device to otolaryngologists and expand OHNS's Biodesign line. Because of Biodesign's excellent handling characteristics, physicians can secure the Biodesign graft during skull-base dura mater reconstruction with or without suturing."

Cook's proprietary Biodesign graft technology is derived from a natural material. It is designed to enable physicians to easily manipulate and secure the graft. Biodesign has been used since 1998 to treat more than 750,000 patients worldwide. Biodesign is non-dermis based and non-cross-linked so that the body can remodel it into strong, well-vascularized tissue.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    COOK MEDICAL INC.. (2019, June 18). Cook Medical launches new treatment option for otolaryngologists. News-Medical. Retrieved on November 05, 2024 from https://www.news-medical.net/news/20140220/Cook-Medical-launches-new-treatment-option-for-otolaryngologists.aspx.

  • MLA

    COOK MEDICAL INC.. "Cook Medical launches new treatment option for otolaryngologists". News-Medical. 05 November 2024. <https://www.news-medical.net/news/20140220/Cook-Medical-launches-new-treatment-option-for-otolaryngologists.aspx>.

  • Chicago

    COOK MEDICAL INC.. "Cook Medical launches new treatment option for otolaryngologists". News-Medical. https://www.news-medical.net/news/20140220/Cook-Medical-launches-new-treatment-option-for-otolaryngologists.aspx. (accessed November 05, 2024).

  • Harvard

    COOK MEDICAL INC.. 2019. Cook Medical launches new treatment option for otolaryngologists. News-Medical, viewed 05 November 2024, https://www.news-medical.net/news/20140220/Cook-Medical-launches-new-treatment-option-for-otolaryngologists.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015